Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Lewis Titterton, Jr. Acquires 8,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. bought 8,000 shares of the stock in a transaction dated Friday, October 23rd. The stock was purchased at an average cost of $2.98 per share, with a total value of $23,840.00. Following the completion of the purchase, the director directly owned 1,054,003 shares in the company, valued at approximately $3,140,928.94. This trade represents a 0.76% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Anixa Biosciences Trading Down 2.0%

Shares of ANIX traded down $0.06 during trading hours on Monday, hitting $2.93. 135,562 shares of the stock traded hands, compared to its average volume of 208,512. Anixa Biosciences Inc has a 1-year low of $2.32 and a 1-year high of $5.46. The firm has a market capitalization of $101.85 million, a PE ratio of -9.16 and a beta of 0.47. The business has a fifty day moving average of $3.00 and a 200-day moving average of $2.99.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). As a group, equities research analysts expect that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ANIX has been the subject of a number of recent research reports. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. HC Wainwright lowered their price objective on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. Weiss Ratings upgraded Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Anixa Biosciences has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIX. Renaissance Technologies LLC boosted its stake in Anixa Biosciences by 13.6% in the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after purchasing an additional 7,300 shares in the last quarter. CoreCap Advisors LLC increased its stake in Anixa Biosciences by 19.2% during the 3rd quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock valued at $182,000 after purchasing an additional 10,000 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in Anixa Biosciences during the 2nd quarter valued at about $29,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Anixa Biosciences in the second quarter worth approximately $29,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Anixa Biosciences in the second quarter worth approximately $30,000. 29.13% of the stock is owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.

Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.